An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

878

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions
Ulcerative Colitis
Interventions
DRUG

RPC1063

Trial Locations (28)

1233

Local Institution - 450, Sofia

1336

Local Institution - 459, Sofia

1606

Local Institution - 451, Sofia

2050

Local Institution - 152, Camperdown

3000

Local Institution - 601, Leuven

4032

Local Institution - 808, Debrecen

8230

Local Institution - 816, Balatonfüred

10676

Local Institution - 643, Athens

12200

Local Institution - 535, Berlin

13353

Local Institution - 525, Berlin

28546

Local Institution - 127, Jacksonville

38138

Local Institution - 179, Germantown

50134

Local Institution - 567, Florence

60453

Local Institution - 112, Oak Lawn

60594

Local Institution - 545, Frankfurt

61039

Local Institution - 954, Kharkiv

70809

Local Institution - 119, Baton Rouge

73112

Local Institution - 290, Oklahoma City

75246

Local Institution - 122, Dallas

76100

Local Institution - 505, Rehovot

85712

Local Institution - 144, Tucson

92801

Local Institution - 102, Anaheim

97239

Local Institution - 143, Portland

210037

Local Institution - 751, Vitebsk

010719

Local Institution - 677, Bucharest

08501

Local Institution - 910, Bardejov

E11 1NR

Local Institution - 236, London

SE1 9RT

Local Institution - 243, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY